ClinicalTrials.gg

Program

danuglipron

Also written as “PF-06882961”, “Danuglipron” and “PF-06882961 (Cohorts 1 and 2)”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Diabetes Mellitus, led by Pfizer.

Furthest: phase 2, since Jun 11, 201918 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer180 open or runningphase 2since Jun 11, 2019Oct 10, 2017none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Oct 10, 2017.

  1. May 7, 2018Phase 1 study in Diabetes Mellitus, Type 2NCT03538743 · 98 enrolled · United States
  2. Jun 11, 2019Phase 2 study in Diabetes Mellitus, Type 2NCT03985293 · 412 enrolled · United States, Bulgaria, Canada and more
  3. Jul 16, 2020Phase 1 study in Healthy VolunteerNCT04495140 · 6 enrolled · Netherlands
  4. Sep 11, 2020Phase 1 study in Diabetes Mellitus, Type 2NCT04552470 · 37 enrolled · Japan
  5. Oct 21, 20203 phase 1 studiesNCT04604496, NCT04616027, NCT04616339
  6. Oct 30, 2020Phase 2 study in Diabetes MellitusNCT04617275 · 151 enrolled · United States
  7. Nov 3, 2020Phase 1 study in ObesityNCT04621227 · 16 enrolled · United States
  8. Jan 11, 2021Phase 2 study in ObesityNCT04707313 · 628 enrolled · United States, Canada, Japan and more
  9. Mar 29, 2021Phase 1 study in Healthy VolunteerNCT04839393 · 27 enrolled · United States
  10. May 12, 2021Phase 1 study in Diabetes Mellitus, Type 2NCT04889157 · 20 enrolled · China
  11. Oct 13, 2021Phase 1 study in Healthy AdultsNCT05093205 · 35 enrolled · United States
  12. Nov 22, 2023Phase 1 study in Healthy ParticipantsNCT06153758 · 33 enrolled · United States
  13. Aug 21, 2024Phase 1 study in ObesityNCT06568731 · 23 enrolled · United States
  14. Mar 12, 2025Phase 1 study in OverweightNCT06910839 · 21 enrolled · United States

TargetBeta

GLP1R →read by rule
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
survodutideBoehringer Ingelheimphase 335
zenagamtideNovo Nordiskphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
SafiglipronJiangsu HengRui Medicinephase 319

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06910839Overweight · United States1TerminatedMay 1, 202521
NCT06568731Obesity · United States1CompletedDec 18, 202423
NCT06153758Healthy Participants · United States1CompletedSep 30, 202433
NCT05093205Healthy Adults · United States1CompletedJul 6, 202235
NCT04889157Diabetes Mellitus, Type 2 · China1CompletedFeb 17, 202220
NCT04839393Healthy Volunteer · United States1CompletedOct 10, 202127
NCT04707313Obesity · United States, Canada, Japan and more2CompletedSep 13, 2023628
NCT04621227Obesity · United States1CompletedMay 13, 202116
NCT04617275Diabetes Mellitus · United States2CompletedNov 17, 2021151
NCT04616339Overweight and/or Obesity · Belgium1CompletedJul 19, 202131
NCT04616027Diabetes Mellitus, Type 2 · United States1CompletedFeb 18, 202242
NCT04604496Hepatic Impairment · United States1CompletedJan 10, 202224
NCT04552470Diabetes Mellitus, Type 2 · Japan1CompletedMar 25, 202137
NCT04495140Healthy Volunteer · Netherlands1CompletedOct 15, 20206
NCT03985293Diabetes Mellitus, Type 2 · United States, Bulgaria, Canada and more2CompletedJun 8, 2021412
NCT03538743Diabetes Mellitus, Type 2 · United States1CompletedMay 23, 201998
NCT03492697Healthy Subjects · United States1CompletedJul 18, 201812
NCT03309241Healthy Subjects · United States1CompletedFeb 21, 201825

How it is read

Names in the registry

  • “PF-06882961”, 16 entries
  • “Danuglipron”, 2 entries
  • “PF-06882961 (Cohorts 1 and 2)”, 1 entry
  • “PF-06882961 (Cohort 3)”, 1 entry
  • “PF-06882961 20 mg”, 1 entry

Codes read as this program: PF06882961.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.